A rare disorder or not? How a child with jaundice changed a nationwide regimen in the Netherlands

[1]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[2]  L. Lesko,et al.  Preemptive Panel-Based Pharmacogenetic Testing: The Time is Now , 2017, Pharmaceutical Research.

[3]  M Schwab,et al.  Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting , 2016, Clinical pharmacology and therapeutics.

[4]  V. Bhutani,et al.  Parental education and the WHO neonatal G-6-PD screening program: a quarter century later , 2015, Journal of Perinatology.

[5]  T. Klausen,et al.  Prevalence of glucose-6-phosphate dehydrogenase deficiency and diagnostic challenges in 1500 immigrants in Denmark examined for haemoglobinopathies , 2015, Scandinavian journal of clinical and laboratory investigation.

[6]  Lucio Luzzatto,et al.  G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications , 2014, British journal of haematology.

[7]  C. Hammerman,et al.  Neonatal screening for glucose-6-phosphate dehydrogenase deficiency: biochemical versus genetic technologies. , 2011, Seminars in perinatology.

[8]  M. Berkovitch,et al.  Medications and Glucose-6-Phosphate Dehydrogenase Deficiency , 2010, Drug safety.

[9]  Ernest Beutler,et al.  The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. , 2009, Blood cells, molecules & diseases.

[10]  M. Cappellini,et al.  Chronic non-spherocytic haemolytic disorders associated with glucose-6-phosphate dehydrogenase variants. , 2000, Bailliere's best practice & research. Clinical haematology.

[11]  H. Notopuro,et al.  Glucose-6-phosphate dehydrogenase deficiency. , 1972, Paediatrica Indonesiana.

[12]  P. Cocco,et al.  Mortality in a cohort of men expressing the glucose-6-phosphate dehydrogenase deficiency. , 1998, Blood.

[13]  M. Belsey.  The epidemiology of favism. , 1973, Bulletin of the World Health Organization.